These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37338204)

  • 1. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
    Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
    Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
    Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
    Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-cigarette Marketing Expenditures in the United States From 2016 to 2021: Targeted Media Outlets Geared Toward People Who Are at Increased Risk for Tobacco Use.
    Ozga JE; Stroup AM; Abadi MH; Cheney MK; Majmundar A; Garrison KA; Chen-Sankey J; Shamblen S; Dunlap C; Stanton CA
    Nicotine Tob Res; 2023 Feb; 25(3):581-585. PubMed ID: 36070398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine pouch marketing strategies in the USA: an analysis of Zyn, On! and Velo.
    Duan Z; Henriksen L; Vallone D; Rath JM; Evans WD; Romm KF; Wysota C; Berg CJ
    Tob Control; 2024 Feb; 33(2):154-163. PubMed ID: 35817549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
    Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
    Tob Control; 2023 Mar; ():. PubMed ID: 36958825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol Marketing Strategies in the United States: An Analysis of Three Prominent Companies.
    Berg CJ; Schauer GL; Cavazos-Rehg P; Romm KF; Wang Y; Wysota CN; Duan Z; Henriksen L
    Cannabis Cannabinoid Res; 2023 Dec; 8(6):1150-1160. PubMed ID: 36169594
    [No Abstract]   [Full Text] [Related]  

  • 10. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.
    Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of FDA's IQOS marketing authorisation and its policy impacts.
    Lempert LK; Glantz S
    Tob Control; 2020 Jun; ():. PubMed ID: 32601147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to IQOS ads and reduced exposure claims, and association with perceived risk from COVID-19 on IQOS purchase and use intentions: results from a web-based survey.
    Sharma A; Fix B; Hyland A; Bansal-Travers M; Quisenberry A; O'Connor R
    Front Public Health; 2023; 11():1307484. PubMed ID: 38269390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IQOS point-of-sale marketing strategies in Israel: a pilot study.
    Bar-Zeev Y; Levine H; Rubinstein G; Khateb I; Berg CJ
    Isr J Health Policy Res; 2019 Jan; 8(1):11. PubMed ID: 30642383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marketing IQOS in a dark market.
    Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
    Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tobacco Product Use and Associated Factors Among Middle and High School Students - National Youth Tobacco Survey, United States, 2021.
    Gentzke AS; Wang TW; Cornelius M; Park-Lee E; Ren C; Sawdey MD; Cullen KA; Loretan C; Jamal A; Homa DM
    MMWR Surveill Summ; 2022 Mar; 71(5):1-29. PubMed ID: 35271557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Young Adults Attend to Health Warnings in the First IQOS Advertisement in the U.S.? An Eye-Tracking Approach.
    Liu J; Phua J; Krugman D; Xu L; Nowak G; Popova L
    Nicotine Tob Res; 2021 May; 23(5):815-822. PubMed ID: 33245339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
    Kim J; Yu H; Lee S; Paek YJ
    Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine Delivery of a Menthol-Flavored Heat-not-Burn Tobacco Product During Directed Use.
    Yingst JM; Bordner C; Hrabovsky S; Hobkirk AL; Trushin N; Richie JP; Foulds J
    Nicotine Tob Res; 2024 Feb; 26(3):397-401. PubMed ID: 37434562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.